Electrical Spinal Cord Stimulation for Upper Extremity Function in Multiple Sclerosis
Transcutaneous electrical spinal cord stimulation + therapy
+ Occupational Therapy
Autoimmune Diseases+4
+ Demyelinating Diseases
+ Immune System Diseases
Treatment Study
Summary
Study start date: August 8, 2024
Actual date on which the first participant was enrolled.This study focuses on exploring a new treatment method for adults with multiple sclerosis (MS), specifically targeting those with difficulties in using their arms and hands. Traditional treatments for MS aim to stop new lesions from forming in the nervous system, but they don't help repair existing damage. This study is important because it looks at a potential new way to restore function and improve quality of life by combining electrical spinal cord stimulation with occupational therapy. This approach could lead to better outcomes in terms of hand and arm function, as well as potentially easing symptoms like pain and muscle stiffness. Participants in the study will undergo two different treatment phases, each lasting six weeks. One phase involves receiving spinal cord stimulation through electrodes placed on the skin, along with occupational therapy. The other phase consists of occupational therapy alone. The order of these treatments will be random, and a six-week break is included between them to clear any effects from the first phase. Researchers will assess if the stimulation is safe and if it effectively improves arm function and symptoms related to quality of life, such as pain and spasticity. The study aims to establish whether adding spinal cord stimulation to therapy offers more benefits than therapy by itself.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.4 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 21 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location